FDA OKs First Liver-Directed Treatment for Metastatic Uveal Melanoma Hepzato Kit melphalan delivery system produced objective responses in 36% of patients Aug 15, 2023
Adjuvant Nivolumab Promising in Resected Merkel Cell Carcinoma Absolute risk reduction of 9-10% in 1- and 2-year DFS compared with observation Jul 14, 2023
Dermatologists Hone Diagnostic Accuracy for Suspect Lesions With AI 'Collaboration' Sensitivity, specificity, mean accuracy, and AUC improved significantly with neural network input May 16, 2023
Allo-Transplant Tied to Better PFS in Advanced Cutaneous T-Cell Lymphomas Results will likely "encourage a practice change," editorialists say May 10, 2023
Responses to PD-1 Blockade Approach 90% in Rare Melanoma "One of the highest tumor response rates we've seen in any cancer," study discussant says Apr 17, 2023
Personalized Cancer Vaccine Boosts Recurrence-Free Survival in Melanoma Clinical implications apply to virtually all solid tumors and possibly hematologic malignancies Apr 17, 2023
FDA OKs Another PD-1 Inhibitor for Merkel Cell Carcinoma Retifanlimab produced responses in 52% of patients with untreated unresectable disease Mar 22, 2023
Vitamin B3 Doesn't Cut Skin Cancer Risk After Organ Transplant Randomized study finds no benefit with 12 months of nicotinamide versus placebo Mar 01, 2023
Long-Term Data Reinforce Targeted Combo Versus Single Agent for Advanced Melanoma Encorafenib-binimetinib tops vemurafenib, but checkpoint inhibitors remain first-line choice Dec 19, 2022
Xeljanz Cancer Risks Detailed New paper provides full results from ORAL Surveillance trial Dec 07, 2022
Melanoma Resistant to Anti-PD-1 Responds to Tumor Infiltrating Lymphocytes Almost a third of patients had objective responses, which deepened over time, study showed Nov 16, 2022
Mixed Results With Fecal Transplant to Stimulate Cancer Immunotherapy Response Encouraging activity with antibiotic-free protocol but not with vancomycin preconditioning Nov 14, 2022
Terry Bradshaw's Merkel Cell Carcinoma After beating bladder cancer, the Hall of Fame quarterback was diagnosed with a rare skin tumor Nov 10, 2022
Immunotherapy First for BRAF Melanoma Edges Out Targeted Combination "Clinically meaningful" improvement in 2- and 3-year survival Sep 28, 2022
Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma Large increase in event-free survival with neoadjuvant plus adjuvant versus only adjuvant therapy Sep 13, 2022
Neoadjuvant Cemiplimab Active in Resectable Cutaneous Squamous Cell Carcinoma Pathologic complete responses seen in 63% of patients in phase II data Sep 12, 2022
Tumor Infiltrating Lymphocytes Reemerge as Potential Melanoma Option More than 50% increase in 6-month PFS versus ipilimumab after progression on first-line anti-PD-1 Sep 12, 2022
Keytruda Plus T-VEC Falls Short in Unresectable Melanoma No significant survival benefit with combination, but certain patients lived longer Sep 02, 2022
Are Skin Lesion Analyzers Ready for Prime Time? FDA panel not fully on board to reclassify computer-aided melanoma detection devices Jul 30, 2022
TKI Plus Immunotherapy Active in Melanoma After Anti-PD-1 Progression More than a fifth of patients responded to lenvatinib-pembrolizumab combination Jul 26, 2022
Something Fishy About Tuna and Melanoma Risk Higher total fish intake linked with 22% higher risk of malignant tumors Jun 09, 2022
Stop Calling It Cancer; AI Gets a Win in Bladder Cancer; Lack of Price Transparency News, features, and commentary about cancer-related issues Apr 22, 2022
Intratumoral Combo Shrinks Melanomas Refractory to Anti-PD-1 But response rate driven primarily by injected lesions, expert points out Apr 14, 2022
Dual Immunotherapy Improves PFS in Melanoma Resistant to Anti-PD-1 Six-month PFS rate more than doubled with nivolumab/ipilimumab versus ipilimumab alone Apr 13, 2022
Novel Fixed-Dose Immunotherapy Combo Wins FDA Approval Nivolumab plus relatlimab doubled progression-free survival in unresectable melanoma Mar 21, 2022
Mixed Message for Ultrasound in High-Risk Cutaneous Head and Neck Cancer Nodal metastasis detected more often than by clinical exam, worrisome false-positive rate Mar 18, 2022
Novel Therapies Active in Head and Neck Cancers High response rate with oncolytic virus plus immunotherapy in cutaneous lesions Feb 28, 2022
Merkel Cell Carcinoma Much More Likely to Recur vs Other Skin Cancers 5-year recurrence rate was 40% compared with 19% for melanoma Feb 23, 2022
Active Surveillance for Melanoma Meets Reality of Loss to Follow-Up More than a third of patients lost to follow-up in "real-world" experience Jan 10, 2022
Melanoma Patient on Immunotherapy Develops Severe Dermatitis Clinicians faced with presumed dermatologic AEs urged to consider all differentials Jan 10, 2022
Long-Term Data Reinforce Standard of Care in Unresectable Melanoma Landmark trial shows median OS of 72.1 months with nivolumab-ipilimumab Dec 01, 2021
Case: VEGFR Inhibition in Merkel Cell Carcinoma Patient Disease stabilized after post-chemotherapy progression of the aggressive neuroendocrine cancer Oct 11, 2021
FDA Issues Orders Clarifying Rules for Marketing Sunscreens But more studies on sunscreen chemicals are still needed, advocacy group says Sep 24, 2021
In RA, Little Risk for Recurrent Cancer With Biologic Treatment Results important because most trials excluded patients with previous cancer, researchers note Sep 23, 2021
Adjuvant Pembrolizumab Boosts Recurrence-Free Survival in High-Risk Melanoma Also, fewer cases of distant recurrences in KEYNOTE-716 trial Sep 19, 2021
9/11 Responders Face Higher Risk of Multiple Cancers Longer follow-up sheds light on the long-term consequences of exposure to disaster site Sep 10, 2021
What's Causing Cancer Patient's Joint Pain While on Checkpoint Inhibitor? Here is how clinicians diagnosed this rare inflammatory side effect Aug 30, 2021
COVID Surges Emerge; FDA Warns About Chantix; Lions, Tigers, Bears Get Vaxxed A daily roundup of news on COVID-19 and the rest of medicine Jul 06, 2021
Start Thinking 'Cure'; One More Hug; Mortgages and Breast Cancer Survival News, features, and commentary about cancer-related issues Jun 16, 2021
Adjuvant Anti-PD-1 Misses on OS in High-Risk Melanoma But pembrolizumab topped active controls for relapse-free survival Jun 07, 2021
